The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.
Although the risk for cardiovascular disease (CVD) is high in individuals with chronic kidney disease (CKD), there are very limited data to guide the use of lipid-lowering drugs (LLDs) in this population because the major trials of LLDs in the general population have included very few individuals with CKD. The pathophysiologic and epidemiologic differences of CVD in the CKD population suggest that the study findings derived in the general population may not be directly applicable to those with CKD, and the few trials that have been directed at patients with kidney disease have not shown clear clinical benefits of LLDs. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Work Group has provided consensus-based guidelines for managing dyslipidemias in individuals with CKD and after renal transplantation. Since the publication of these statements, further data have emerged and multiple studies are ongoing to define better the role of LLDs in patients with CKD. In this article, the data that are pertinent to the CKD population are reviewed, and updated recommendations for use of LLD in the CKD population are provided.
Nogueira
Joseph
J
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. jnogueir@medicine.umaryland.edu
Weir
Matthew
M
D002318:Cardiovascular Diseases / Q000209:etiology*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications*; D017410:Practice Guidelines as Topic
D000960:Hypolipidemic Agents